Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: Case report

INTRODUCTION: Eculizumab has been shown to be an effective and typically well-tolerated medication in the treatment of neuromyelitis optica spectrum disorder (NMOSD) in maintaining disease remission in patients who are aquaporin-4 water channel autoantibody (AQP4-IgG) seropositive. The efficacy of e...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatterton, Sophie, Parratt, John Douglas Edward, Ng, Karl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393544/
https://www.ncbi.nlm.nih.gov/pubmed/36003301
http://dx.doi.org/10.3389/fneur.2022.951423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393544/
https://www.ncbi.nlm.nih.gov/pubmed/36003301
http://dx.doi.org/10.3389/fneur.2022.951423

Ejemplares similares